The global PCSK9 inhibitors market is on pace for impressive growth, with 2024 revenues expected to surge to US$ 2,733.7 million. Forecasted to expand at a remarkable compound annual growth rate (CAGR) of 18.7% until 2034, the market is expected to peak with total sales of US$ 15,140.3 million, indicating the rising need for novel …